Michael Feld Sells 165 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 165 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $157.13, for a total transaction of $11,784.75.
• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $152.80, for a total transaction of $11,460.00.

Becton, Dickinson and Company Trading Up 0.8%

BDX stock opened at $189.71 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The company has a market cap of $52.27 billion, a price-to-earnings ratio of 57.14, a PEG ratio of 13.26 and a beta of 0.19. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $166.14 and a 200-day simple moving average of $160.53.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the firm posted $3.68 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds have recently bought and sold shares of BDX. Larson Financial Group LLC grew its position in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 53 shares in the last quarter. Atlantic Union Bankshares Corp increased its stake in Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after buying an additional 57 shares during the period. Elevation Point Wealth Partners LLC increased its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC lifted its position in Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock worth $834,000 after buying an additional 62 shares in the last quarter. Finally, BOK Financial Private Wealth Inc. boosted its stake in shares of Becton, Dickinson and Company by 7.3% during the 2nd quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock valued at $162,000 after buying an additional 73 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Finally, Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.